Phase II, randomised, observer-blind, placebo-controlled,multicentre study to assess the safety, immunogenicity and efficacy of GSK Bilologicals ' Herpes Zoster HZ/su candidate vaccine to adults aged 18 years and older with haematologic malignancies.